These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
78 related articles for article (PubMed ID: 22958293)
21. Cyclin E confers a prognostic value in premenopausal breast cancer patients with tumours exhibiting an infiltrative growth pattern. Berglund P; Stighall M; Jirström K; Rydén L; Fernö M; Nordenskjöld B; Landberg G J Clin Pathol; 2008 Feb; 61(2):184-91. PubMed ID: 17483245 [TBL] [Abstract][Full Text] [Related]
22. Cyclin E1 (CCNE1) as independent positive prognostic factor in advanced stage serous ovarian cancer patients - a study of the OVCAD consortium. Pils D; Bachmayr-Heyda A; Auer K; Svoboda M; Auner V; Hager G; Obermayr E; Reiner A; Reinthaller A; Speiser P; Braicu I; Sehouli J; Lambrechts S; Vergote I; Mahner S; Berger A; Cacsire Castillo-Tong D; Zeillinger R Eur J Cancer; 2014 Jan; 50(1):99-110. PubMed ID: 24176298 [TBL] [Abstract][Full Text] [Related]
23. Quantitative expression of the human kallikrein gene 9 (KLK9) in ovarian cancer: a new independent and favorable prognostic marker. Yousef GM; Kyriakopoulou LG; Scorilas A; Fracchioli S; Ghiringhello B; Zarghooni M; Chang A; Diamandis M; Giardina G; Hartwick WJ; Richiardi G; Massobrio M; Diamandis EP; Katsaros D Cancer Res; 2001 Nov; 61(21):7811-8. PubMed ID: 11691797 [TBL] [Abstract][Full Text] [Related]
24. p27Kip1 expression is associated with clinical outcome in advanced epithelial ovarian cancer: multivariate analysis. Masciullo V; Ferrandina G; Pucci B; Fanfani F; Lovergine S; Palazzo J; Zannoni G; Mancuso S; Scambia G; Giordano A Clin Cancer Res; 2000 Dec; 6(12):4816-22. PubMed ID: 11156240 [TBL] [Abstract][Full Text] [Related]
25. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1. Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777 [TBL] [Abstract][Full Text] [Related]
26. Human kallikrein gene 5 (KLK5) expression is an indicator of poor prognosis in ovarian cancer. Kim H; Scorilas A; Katsaros D; Yousef GM; Massobrio M; Fracchioli S; Piccinno R; Gordini G; Diamandis EP Br J Cancer; 2001 Mar; 84(5):643-50. PubMed ID: 11237385 [TBL] [Abstract][Full Text] [Related]
27. Prognostic value of CA 125 in ovarian cyst fluid of patients with epithelial ovarian cancer. Kolwijck E; Span PN; Thomas CM; Bulten J; Sweep FC; Massuger LF Oncol Rep; 2010 Feb; 23(2):579-84. PubMed ID: 20043124 [TBL] [Abstract][Full Text] [Related]
28. BTF4/BTNA3.2 and GCS as candidate mRNA prognostic markers in epithelial ovarian cancer. Le Page C; Ouellet V; Quinn MC; Tonin PN; Provencher DM; Mes-Masson AM Cancer Epidemiol Biomarkers Prev; 2008 Apr; 17(4):913-20. PubMed ID: 18398031 [TBL] [Abstract][Full Text] [Related]
29. Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer. Nakayama N; Nakayama K; Shamima Y; Ishikawa M; Katagiri A; Iida K; Miyazaki K Cancer; 2010 Jun; 116(11):2621-34. PubMed ID: 20336784 [TBL] [Abstract][Full Text] [Related]
30. [Prognostic value of cyclin E and its relation to blood vessel invasion in rectal cancer]. Zhou YJ; Wan FL; Yao LH; Feng LY Zhonghua Wei Chang Wai Ke Za Zhi; 2008 Mar; 11(2):167-71. PubMed ID: 18344087 [TBL] [Abstract][Full Text] [Related]
31. Overexpression of cyclin D1 is associated with poor survival in epithelial ovarian cancer. Barbieri F; Lorenzi P; Ragni N; Schettini G; Bruzzo C; Pedullà F; Alama A Oncology; 2004; 66(4):310-5. PubMed ID: 15218299 [TBL] [Abstract][Full Text] [Related]
32. Aurora-B protein expression is linked to initial response to taxane-based first-line chemotherapy in stage III ovarian carcinoma. Beussel S; Hasenburg A; Bogatyreva L; Hauschke D; Werner M; Lassmann S J Clin Pathol; 2012 Jan; 65(1):29-35. PubMed ID: 22011448 [TBL] [Abstract][Full Text] [Related]
33. VEGF-A and i-NOS expression are prognostic factors in serous epithelial ovarian carcinomas after complete surgical resection. Engels K; du Bois A; Harter P; Fisseler-Eckhoff A; Kommoss F; Stauber R; Kaufmann M; Nekljudova V; Loibl S J Clin Pathol; 2009 May; 62(5):448-54. PubMed ID: 19126566 [TBL] [Abstract][Full Text] [Related]
34. The prognostic value of pre-operative serum tetranectin, CA-125 and a combined index in women with primary ovarian cancer. Høgdall CK; Nørgaard-Pedersen B; Mogensen O Anticancer Res; 2002; 22(3):1765-8. PubMed ID: 12168866 [TBL] [Abstract][Full Text] [Related]
35. Which cyclin E prevails as prognostic marker for breast cancer? Results from a retrospective study involving 635 lymph node-negative breast cancer patients. Sieuwerts AM; Look MP; Meijer-van Gelder ME; Timmermans M; Trapman AM; Garcia RR; Arnold M; Goedheer AJ; de Weerd V; Portengen H; Klijn JG; Foekens JA Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3319-28. PubMed ID: 16740753 [TBL] [Abstract][Full Text] [Related]
36. Implication of malignancy and prognosis of p27(kip1), Cyclin E, and Cdk2 expression in epithelial ovarian tumors. Sui L; Dong Y; Ohno M; Sugimoto K; Tai Y; Hando T; Tokuda M Gynecol Oncol; 2001 Oct; 83(1):56-63. PubMed ID: 11585414 [TBL] [Abstract][Full Text] [Related]
37. The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients. Begum FD; Høgdall CK; Kjaer SK; Christensen L; Blaakaer J; Bock JE; Glud E; Høyer-Hansen G; Ring-Larsen H; Høgdall EV Anticancer Res; 2004; 24(3b):1981-5. PubMed ID: 15274388 [TBL] [Abstract][Full Text] [Related]